Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Private-label prosperity picks up Perrigo: The Allegan, Mich.-based firm says its consumer health care segment sales grew 12 percent to $419.1 million during its fiscal 2009 third quarter, including a $39 million increase attributable to the acquisitions of JB Labs, Unico Holdings, Laboratorios Diba and Brunel Pharma. "Consumers are realizing the value of store brands in a challenging economy," said President and CEO Joseph Papa, citing 11.7 percent growth of the U.S. OTC store brand market in the quarter. "Perrigo is uniquely positioned to deliver that value to consumers," he added during a May 7 earnings call. The private labeler reported net sales of $505.9 million for the January-March period, up 5.3 percent from $480.6 million, and setting a company quarterly earnings per-share record of 50 cents, up from 42 cents in the year-ago quarter. Papa touted the nearly 40 percent market share of omeprazole, equivalent to Procter & Gamble's Prilosec OTC, and added that Perrigo projects full-year sales of that generic to reach the high end of its guidance range of $150 million to $200 million (1"The Tan Sheet" Feb. 9, 2009, p. 12). Perrigo also announced it is seeking to divest its Israel consumer products segment, which includes Careline beauty brands. Sales for the Israel business dropped 22 percent to $18 million from $23 million during the quarter

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts